Navigation Links
Liver-cell transplants show promise in reversing genetic disease affecting liver and lungs
Date:4/22/2011

April 21, 2011 -- (Bronx, NY) -- Transplanting cells from healthy adult livers may work in treating a genetic liver-lung disorder that affects millions of people worldwide, according to an animal study in the April 18 online edition of the Journal of Clinical Investigation. Jayanta Roy-Chowdhury, M.D. , professor of medicine and of genetics at Albert Einstein College of Medicine of Yeshiva University, is the study's senior author.

The genetic disorder, alpha-1 antitrypsin (AAT) deficiency, is the most common potentially lethal hereditary disease among Caucasians, affecting an estimated 100,000 people in the United States and 3.4 million people worldwide. AAT is a protein made by the liver that is essential for lung health. In AAT deficiency, the liver produces a misshapen form of AAT that cannot enter the bloodstream and instead gets stuck inside liver cells, causing two major problems:

  • AAT accumulates in the liver, leading to fibrosis (development of scar tissue) and liver failure;
  • Too little AAT reaches the lungs, where it's needed to rein in elastase, an enzyme produced by white blood cells. Elastase helps kill bacteria in the lungs, but uncontrolled elastase activity can damage lung tissue and lead to severe emphysema (chronic obstructive pulmonary disease).
  • In the study, Dr. Roy-Chowdhury and his colleagues tested cell therapy on transgenic mice whose liver cells (hepatocytes) had been engineered to produce mutant human AAT, resulting in liver fibrosis. When the mice were given infusions of hepatocytes harvested from the livers of healthy mice, the transplanted cells proliferated in the host liver, progressively replacing diseased hepatocytes. Most importantly, said Dr. Roy-Chowdhury, the transplanted cells reversed the fibrosis that had developed.

    Current therapy for AAT deficiency consists of life-long injections of a genetically engineered version of AAT called Prolastin. "This very expensive therapy slows progression of the lung disease in some patients but does not have any beneficial effect on the liver disease," said Dr. Roy-Chowdhury. The only other therapy for AAT deficiency is combined lung-liver transplantation, which is reserved for the sickest patients.

    "These promising results in animals indicate that it may be worthwhile to investigate the usefulness of hepatocyte transplantation for AAT deficiency as well as a variety of other inherited liver-based disorders," said Dr. Roy-Chowdhury.


    '/>"/>

    Contact: Kim Newman
    sciencenews@einstein.yu.edu
    718-430-3101
    Albert Einstein College of Medicine
    Source:Eurekalert

    Related medicine news :

    1. Internal Anthem Blue Cross/WellPoint Document: Only Patients Who Push Back Get Covered Out of State Liver Transplants
    2. Los Angeles Hair Transplant Cosmetic Surgeon Corrects Bad Hair Transplants With New Hair Restoration Method
    3. Kidney transplants: Expanding the pool of available organs
    4. Patients with treatment-resistant CLL respond positively to stem cell transplants
    5. Hispanics and Asians less likely to receive liver transplants
    6. Biosynthetic Corneas Show Promise in Transplants
    7. OHSU research suggests compound administered during some bone marrow transplants elevates risks
    8. Kidney Transplants for Elderly Double Over Decade
    9. HIV Patients Do Well After Kidney Transplants: Study
    10. 2 people receive kidney transplants in pilot program using CMU software
    11. Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2017)... ... July 28, 2017 , ... Mirror Mirror Beauty Boutique was ... the most successful CoolSculpting practices across the country are annually honored. This marks ... coveted Diamond Level status, the highest ranking possible. , CoolSculpting is a ...
    (Date:7/28/2017)... LAND O' LAKES, FL (PRWEB) , ... July ... ... Acute Care Hospital (LTACH) received the Vapotherm Center of Excellence designation for use ... is the highest recognition a facility can receive from Vapotherm, and signifies that ...
    (Date:7/28/2017)... ... July 28, 2017 , ... Nominated for ... Chain Partners for 2017. MEBC received numerous client nominations from customers who ... Berger, SupplyChainBrain’s publisher, says “For 15 years running, SupplyChainBrain has published our much-anticipated ...
    (Date:7/28/2017)... , ... July 28, 2017 , ... James M. Maisel, ... to have chaired the Epidemiology and Prevention of Diabetes section at the 5th World ... also chairman of Retina Group of New York and recipient of the Juvenile Diabetes ...
    (Date:7/28/2017)... ... 28, 2017 , ... The United States Department of Agriculture ... programs. , Right now the most public debate is over the Supplemental Nutrition ... are under consideration, including WIC (Women, Infants, and Children), which is the country’s ...
    Breaking Medicine News(10 mins):
    (Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
    (Date:7/10/2017)... 10, 2017 The Institute for In Vitro ... the recipient of a VITROCELL® inhalation exposure system thanks ... Consortium. The device, which is designed to replace animals ... lung cells to airborne test materials in an environment ... VITROCELL® system for testing combustible tobacco products, as well ...
    (Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston ... and unparalleled access to global decision makers and innovative ... 800+ life science leaders during two impactful days. BioPharm ... provides delegates with additional networking opportunities with 4,500+ life ...
    Breaking Medicine Technology: